The signal was in the repetition. Across APAC this year, Precision for Medicine’s regional leaders have been in the rooms where global development strategy is being debated, from CMAC 2026 in Suzhou to Clinical Trials Festival Asia in Singapore to a China-based industry webinar. The topics kept changing: dose optimization, small-molecule differentiation, MRCT planning, and Australia’s early-phase role. The underlying concern did not.
Sponsors are realizing that APAC is no longer just where global development gets executed. It is increasingly where global evidence strategy gets shaped.
The protocol gets written. The countries are chosen. The dose logic is fixed. The comparators make sense in one market and less so in another. Months later, someone finally asks whether the evidence will travel.
That question connects the conversations our teams are leading across the region. The better model is not simply “global strategy”, but evidence that travels – less abstract, more durable when regulatory scrutiny begins.
At CMAC, Zhenfei Yin used oncology dose optimization to highlight a broader development problem.
For years, dose selection was treated as an early hurdle: identify a tolerable range, establish a regimen and carry it forward. That handoff model is becoming harder to defend.
In oncology especially, dose decisions now shape downstream elements: patient selection, benefit-risk interpretation, label potential, and cross-regional regulatory alignment. A dose that looks workable in isolation can still fail if it is disconnected from the strategy - population, biomarker, endpoint, and access.
The more useful question is what that dose needs to make possible later.
A coherent and defensible label
A population strategy that translates across regions
A regimen, biomarker, and endpoint package aligned with regulator and clinicians’ expectations.
Dose needs to enter the global evidence conversation earlier. If it comes too late, the program may still progress – but the evidence may not travel.
The same pressure shows up later in development, where differentiation must hold beyond initial scientific rationale.
In a CMAC panel on small-molecule drug development, Jing Ping Yeo, PhD shifted the discussion from modality to market reality. Small molecules retain advantages – scalability, cost – but those advantages are no longer sufficient on their own.
Relevance remains. Margin for weak positioning does not.
The development narrative has to be clinically differentiated for clinicians, durable under regulatory scrutiny, and adaptable across markets with different value expectations.
That pushes key questions upstream:
MRCT’s ultimately test these answers. They do not just assess operational execution – they expose whether the development logic holds under global scrutiny.
Regulators have limited tolerance for regionally generated data repackaged for global submission. ICH E17 and E8 reinforce expectations around global relevance, population differences, quality-by-design principles, and the Target Product Profile.
So, the sponsor question gets sharper.
Execution proves you can run a trial. Evidence proves you have a strategy.
Australia makes the pattern easier to see because the advantages are concrete.
Zhenfei Yin and James Cheong, speaking across the regional webinar and Clinical Trials Festival Asia, described a familiar market in a more strategic role. Australia has long been attractive for early-phase trials. Fast startup. A practical CTN pathway. Globally accepted data. Meaningful R&D incentives.
The details matter because they change what a sponsor can choose next:
Fast startup timelines of approximately 8–12 weeks
The CTN pathway with no requirement for IND
Data accepted by FDA, EMA, and PMDA
Up to 43.5% R&D tax incentives
The real value shows up when the first study is built to keep the next move open.
Start fast, then hope the data travels is suboptimal. Better teams ask the harder question before first patient in. What does this Phase 1 decision need to make possible six months from now?
|
Stage |
Geographic Setup |
Strategic Role |
|
Phase 1 |
Australia |
Rapid signal generation and dose establishment |
|
Expansion |
Australia + US |
Building globally aligned data |
|
MRCT |
Australia + US + China |
Supporting global registration |
Built with the U.S., China, and the broader MRCT pathway in mind, Phase 1 in Australia can do more than accelerate startup. It can keep the next door from closing too soon.
Coverage only gets you so far. Precision for Medicine’s APAC footprint spans mainland China, Hong Kong, Taiwan, Japan, Singapore, South Korea, Australia, India, and beyond. While that reach matters, a map is not a strategy as it won’t tell you whether the data, endpoints, sites, and regulatory assumptions will hold together when the program crosses borders.
We leverage our footprint to let sponsors design earlier:
Biomarker strategy connected to the clinical plan
Translational, clinical, and commercial considerations visible before the protocol locks
Country selection that reflects patient access, regulatory expectations, and future market needs
Governance that keeps data quality and escalation paths from fragmenting across regions
This is how APAC moves from regional coverage to development design. The same pressure runs through dose strategy, differentiation, MRCT planning, Australia’s early-phase role, and regulatory readiness to make the evidence travel before the program hardens.
Execution remains essential. A strategy that cannot activate sites, recruit patients, manage data, or satisfy regulators will fail regardless of design. The programs with the best chance to succeed globally make critical decisions earlier:
Which countries are integral to the evidence strategy?
Which populations drive regulatory and commercial success?
Which endpoints, comparators, and dose decisions remain valid across regions?
That is why the conversations happening across APAC matter now. They are not separate conference takeaways or isolated regional observations. They point to a structural shift: design capability is becoming central to the region’s role in global development. Value is created earlier – at country selection, endpoint definition, dose strategy, and the moment someone decides whether this evidence will still make sense beyond the first market.
This is the rationale behind Precision for Medicine’s APAC expansion and why our regional leaders are actively shaping these discussions: to help sponsors make the global decisions earlier, while there is still time to influence the evidence.
If you are planning an APAC-first, APAC-inclusive, or globally intended program, now is the time to pressure-test whether your evidence strategy will travel.
If your global program only becomes global after the first key of decisions are made, how much strategy have you already given away?